Onego Bio Secures EUR 14 million in New Funding
18 July 2024
Agronomics Ltd
("Agronomics" or the "Company")
Onego Bio Secures EUR 14 million in New Funding
Agronomics (LSE: ANIC), a leading listed company in the field of cellular agriculture, is pleased to announce that its portfolio company, Onego Bio Ltd ("Onego") has secured EUR 14 million in new funding from the European Innovation Council Accelerator Program and an additional Series A investor. In April, Onego announced it closed EUR 37 million in its series A round which, including this new capital, brings Onego's total funding to date to EUR 65 million.
Agronomics has invested EUR 8.4 million into Onego since inception which, subject to audit, is currently carried at GBP 11.1 million (EUR 12.9 million) and will not change as a result of this fundraise. This position accounts for approximately 6.7% of Agronomics' last published Net Asset Value (31/03/2024), including post-balance sheet adjustments. Agronomics has an equity ownership of 16.1% on a fully diluted basis.
For a short video on Onego, please visit: https://www.agronomics.im/news/onegobio
The full announcement is set out below without any material changes:
HELSINKI, FI, July 17, 2024 - Onego Bio, a leading precision fermentation company, has secured €14M / $15.2M in new funding from the European Innovation Council Accelerator Program and additional Series A investors. In 2024 Onego Bio has successfully raised €50.5M / $55M, bringing the company's total funding to €65M / $70.8M.
Manufactured as an industrial food ingredient, Onego's Bioalbumen® is a bio-identical egg protein with full functionality, perfect protein quality and a neutral taste. Bioalbumen® offers a stable supply of egg protein while having the potential to alleviate the environmental burden by ~90 %.
As a US-Finnish company, Onego is moving at full speed to commercialise in North America, where the regulatory landscape allows a faster market entry. The company is on track to submit a Generally Recognized as Safe (GRAS) notice to the FDA this year, with the hope of receiving a "no questions" letter from the FDA in 2025. The newly gained EIC funding will fuel the company's go-to-market plan both in the US and in the EU, including securing regulatory approval from the European Food Safety Authority (EFSA).
Maija Itkonen, CEO & co-founder of Onego Bio said:
"The new funding and immense support from our investors demonstrates their confidence in our vision and the potential of innovations like Bioalbumen® to build a more sustainable system. It also shows that the EU recognizes precision fermentation as a solution to address sustainability issues and enhance food security in Europe and worldwide. However, to remain competitive and fully capture the potential of exceptional European research and innovation, the regulatory approval process must be accelerated, as the EU currently lags behind other regions in this area."
Onego Bio was selected for EIC funding from a highly competitive pool of 969 applicants, of which 347 companies were interviewed by juries of experienced investors and entrepreneurs, with only the top 68 receiving funding. EIC Accelerator selects startups or SMEs with a high-impact product, service, or business model that demonstrates the potential to scale up, create new markets or disrupt existing ones in Europe and even worldwide. In the 2024 work program, EIC has identified precision fermentation as an area where breakthrough technologies or game-changing innovations can have a major impact. Precision fermentation can improve the sustainability, efficiency, and resilience of European food supply chains by decoupling food production from the soil and minimizing its environmental impact.
About Agronomics
Agronomics is a leading London-listed company focussing on investment opportunities within the field of cellular agriculture. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to invest in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals and improve food security for the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.
For further information please contact:
|
Agronomics Limited |
Beaumont Cornish Limited |
Canaccord Genuity Limited |
Cavendish Securities Plc |
Peterhouse Capital Limited |
SEC Newgate |
|
The Company |
Nomad |
Joint Broker |
Joint Broker |
Joint Broker |
Public Relations |
|
Jim Mellon Denham Eke |
Roland Cornish James Biddle |
Andrew Potts Harry Pardoe Alex Aylen (Head of Equities) |
Giles Balleny Michael Johnson |
Lucy Williams Charles Goodfellow |
Bob Huxford Anthony Hughes |
|
+44 (0) 1624 639396 info@agronomics.im |
+44 (0) 207 628 3396 |
+44 (0) 207 523 8000 |
+44 (0) 207 397 8900 |
+44 (0) 207 469 0936 |
agronomics@secnewgate.co.uk |
Nominated Adviser
Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 4 hours ago Johnson Matthey
- 5 hours ago Galliford Try
- 5 hours ago Galliford Try
- 5 hours ago Centrica
- 6 hours ago Smith & Nephew